Format

Send to

Choose Destination
Onco Targets Ther. 2019 Nov 14;12:9663-9668. doi: 10.2147/OTT.S210699. eCollection 2019.

Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review.

Author information

1
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
2
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
3
Department of Oncology, The Fifth People's Hospital of Dalian, Dalian, People's Republic of China.
#
Contributed equally

Abstract

The incidence of lung neuroendocrine carcinomas, which originate from lung neuroendocrine cells, is 1.35/100,000, among which mixed neuroendocrine carcinomas are very rare. Because of the heterogeneity and significant differences in sensitivity to treatments, there is no effective treatment, and the prognosis is poor. In this article, we report the diagnosis and treatment of a case of mixed neuroendocrine carcinoma of the lung in our hospital. During the treatment, the patients had significant myelosuppression after initial chemotherapy, but benefited from oral chemotherapy consisting of a combination of capecitabine and temozolomide (CAPTEM). The report was approved by the affiliated Cancer Hospital of Shandong University.

KEYWORDS:

case report; lung cancer; mixed neuroendocrine carcinoma; poor tolerance; review; temozolomide

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center